Clopidogrel goes generic (USA)

On May 17, 2012, the FDA approved generic versions of the blood thinning drug clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis), which helps reduce the risk of heart attack and stroke. Clopidogrel is FDA approved to treat patients who have had a recent heart attack or a recent stroke, or have partial or total blockage of an artery (peripheral artery disease). The anticipation of this generic approval of this popular drug has led many to question its affect on the antiplatelet drug market. "For people who must manage chronic health conditions, having effective and affordable treatment options is important," said Keith Webber, PhD, deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research. "The generic products approved today will expand those options for patients."